Nkarta, Inc. (NKTX) AI Stock Analysis

Nkarta, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for cancer treatment. Founded in 2015 and based in South San Francisco, California, the company specializes in cellular immunotherapies utilizing natural killer (NK) cells. Its approach engineers NK cells with chimeric antigen receptors (CARs) on their surface to target and attack specific tumor proteins. Its co-lead product candidates include NKX101, which is in Phase I trials for relapsed/refractory acute myeloid leukemia or higher-risk myelodysplastic syndromes, and NKX019, which is in pre-clinical development targeting CD19 for B cell malignancies. Nkarta also maintains a research collaboration agreement with CRISPR Therapeutics AG.

Nkarta generates negligible commercial revenue as a clinical-stage company. Revenue dropped from $6.5M in FY2018 to $115,385 in FY2019, and fell further to $385 in FY2020, representing a two-year revenue CAGR of -99.2%. Net losses widened substantially over that timeframe, from -$274,503 in FY2018 to -$21.1M in FY2019 and -$91.4M in FY2020, driven by research and development expenses expanding to $36.2M in FY2020. Free cash flow was -$51.0M in FY2020 compared to -$5.9M in FY2018. Over the trailing twelve months ended June 30, 2026, revenue stood at $385, while EPS was -$1.58.

As of June 30, 2026, Nkarta held $182.8M in cash and short-term investments against total debt of $73.5M, resulting in net cash of $109.2M. The company maintains a current ratio of 7.98 and a debt-to-equity ratio of 0.30, supported by shareholders' equity of $247.7M and total assets of $337.6M. Capital expenditures were $1.2M in FY2025. Financing activities have contributed to dilution, with the five-year share count change rising 126.1%.

Nkarta carries a market capitalization of $128.9M and an enterprise value of $87.7M. The stock trades at a price-to-book ratio of 0.8x and an EV to EBITDA multiple of 0.9x, compared to the median of its US-listed Healthcare peers of 12.0x EV to EBITDA. Over the past year, NKTX declined 27.7%, trailing the S&P 500 (SPY) gain of 16.8%. Over a five-year period, the stock fell 90.2%, compared to an 83.0% return for the S&P 500.

Wall Street coverage includes 6 Strong Buy ratings, 1 Buy rating, and no Hold or Sell ratings. The mean price target is $10.83, representing an upside of 501.8% over the last close of $1.80 on October 16, 2026. For the current fiscal year ending December 31, 2026, consensus estimates project revenue of $0 and EPS of -$1.71. For the next fiscal year, 3 analysts estimate revenue of $0 and EPS of -$1.75. Nkarta beat EPS estimates in 1 of the last 4 quarters, with its next earnings date scheduled for November 9, 2026.

This page is an AI-written research summary of Nkarta, Inc. (NKTX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: NKTX income statement, NKTX balance sheet, NKTX key metrics, NKTX analyst forecast, NKTX chart. See the NKTX stock overview for the latest quote and news.